Empresa ContraVir Pharmaceuticals Inc Nasdaq
Acciones
US21234W1036
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/01/16 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/10/19 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Daniel Trepanier
PRN | Corporate Officer/Principal | - | 03/10/19 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/05/13 |
Timothy Block
BRD | Director/Board Member | 69 | 26/11/13 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/06/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 1 688 | 0 | 0 | 99,69 % |
Acción B | 1 | 5 473 126 | 5 456 345 ( 99,69 %) | 0 | |
Acción C | 0 | 85 581 | 0 | 0 |
Información de la empresa
Hepion Pharmaceuticals, Inc.
399 Thornall Street 1st Floor
08837, Edison
+732 902 4000
http://www.hepionpharma.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+16,73 % | 121 mil M | |
+13,04 % | 107 mil M | |
-5,80 % | 24,82 mil M | |
+1,69 % | 22,48 mil M | |
-10,09 % | 18,32 mil M | |
-40,52 % | 16,33 mil M | |
-14,00 % | 15,31 mil M | |
+1,18 % | 14,08 mil M | |
+24,18 % | 11,74 mil M |